Detalhe da pesquisa
1.
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
N Engl J Med
; 385(27): 2531-2543, 2021 12 30.
Artigo
Inglês
| MEDLINE | ID: mdl-34965338
2.
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
BMC Infect Dis
; 21(1): 5, 2021 Jan 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33446115
3.
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial.
Lancet HIV
; 9(9): e638-e648, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-36055295